Last updated: 2026-09-21 17:39:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
KALA BIO, Inc. (KALA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.57, with a market capitalization of $10.42M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.49 to $988.50. This page covers its latest market performance, valuation, price trends and company information.
$10.42M | |
$0.57 | |
$66,808.19 | |
$0.49 | |
$0.54 | |
25.71K | |
327.98K | |
-- | |
$988.50 | |
$0.49 | |
-- | |
-- |
KALA BIO, Inc. (KALA) is currently trading at $0.57 as of 2026-09-21 17:37:00, up 5.75% ($0.03) from the previous close of $0.54
During today's regular trading session, KALA has traded between $0.49 and $66,808.19, with a trading volume of 25.71K shares. The current price is near the lower end of today's range.
Over the past seven days, KALA BIO, Inc. (KALA) moved from $0.56 to $0.57, representing a gain of 1.26% ($0.01).
The stock traded between $0.50 and $0.60 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 166.34 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.0%
KALA is currently trading at $0.57, placing it 0.0% of the way from its 52-week low of $0.49 to its 52-week high of $988.50. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 6 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of KALA BIO, Inc. (KALA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.